A common misconception is that you need a lot of money to invest in the stock market. Let's look at three healthcare stocks that can be purchased for $100 and have good prospects to grow over time. The stock hasn't been off to a great start this year, dipping 18%, but the odds look pretty good for the company in the near future.
AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). Let's examine the data from the clinical trial and the U.S. UC market to resolve this question. Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes damage to the gastrointestinal (GI) tract.
Both of these stocks are Dividend Kings, and their payouts are likely to continue rising in the future.